FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Lilly Agrees to Buy Cancer Biotech Kelonia for Up to $7 Billion
Scientific American May 2026 Cover Story Details New Research and Treatments for Heart Disease
California ISO Selects LS Power Affiliate for New Competitive Transmission Project in the Bay Area
OpenAI Announces Departure of Three Executives
S&P 500 Declines as Oil Prices Rise Amid U.S.-Iran Tensions
Amsterdam Introduces Supervised Self-Driving Tesla
National Airlines to Launch First 777 Freighter in May
Dow Jones Index Declines Amid Rising U.S.-Iran Tensions
McKesson Enters Agreement with Apollo Funds for Minority Stake in Medical-Surgical Solutions
Q4 Earnings Review Highlights Performance of Upstream E&P Sector
US Equity Futures Decline Amid Rising Middle East Tensions
Pakistan's Interior Minister Meets Iranian Ambassador to Discuss Diplomatic Relations
Jefferies Raises Tesla Price Target Amid Execution Concerns
Psychedelic Drug Stocks Soar as Trump Orders FDA to Expedite Approvals
Vertical Aerospace (EVTL) Stock Plunges 10% Following $850M Financing Agreement
Morgan Stanley Picks Memory Makers Micron and Sandisk Over Intel (INTC) and AMD (AMD) for AI Exposure
As the film, "The Story of Everything," Explores the Nature of Reality, a New Book from Oaklea Press Argues: "You Are Not Your Brain"- and That Changes Everything
Milei’s Auction of Argentine Railroads Risks Sidelining US-Backed Bidder
US Homebuilders Set for Another ‘Lost’ Earnings Season
Propane Education & Research Council Commits $6 Million to Nexio to Advance Propane Commercial Vehicle Certification
NeutronX Secures CAGE Code; Launches Federal Bidding Strategy Positioning NextNRG (NASDAQ: NXXT) to Target U.S. Energy Security and Infrastructure Contracts
OT Security Experts Warn: Your Team Isn't the Problem. Your Architecture Is.
Inside one of Amsterdam’s first supervised self-driving Teslas
Abu Dhabi’s Zayed airport opens for non-flying shoppers
NYSE Content Update: SEC Chair Paul Atkins to Ring Opening Bell at NYSE
Revolut Aims for $150 Billion Valuation Ahead of IPO
T-Mobile US Enhances Partnership with Rogers Communications
Delta Air Lines Shares Surge 84% Over Past Year
CenterWell Launches Fulfillment Index to Define Aging Well
Mastercard Integrates AI Payment Solutions to Enhance Digital Commerce Trust
Shell Negotiates Sale of South African Fuel Retail Business to ADNOC
Apple 'Relatively Insulated' From AI Volatility, Analyst Says
Kuwait Announces Force Majeure on Oil Shipments Amid Hormuz Disruptions
USA Rare Earth to Buy Brazilian Miner in $2.8 Billion Deal
Affiliates of Blue Owl to buy healthcare REIT Sila Realty Trust for $2.4 Billion
Canada’s annual CPI rises to 2.4% as Iran war spikes gasoline costs
Nakheel awards $144m Dubai Islands infrastructure contract
AI surges as focus for strategic planning
NATO'S RUTTE TO MEET ERDOGAN IN ANKARA APR. 21-22...
CaixaBank Plans 60% Workforce Expansion in London
AST SpaceMobile Shares Decline Following Satellite Deployment Error
Canada's March Inflation Rate Rises to 2.4% Amid Energy Price Surge
AST SpaceMobile Stock Declines Following Satellite Loss in Blue Origin Launch
Accenture Collaborates with Avanade and Microsoft on AI Factory Intelligence System
PayPay Corporation Debuts on Nasdaq, Marking Key Development for Japanese Tech Sector
Study Highlights Predictive Value of Ignite Proteomics' RPPA Platform for Breast Cancer Therapy
GE Vernova Faces Legal Challenges Amid Growing Energy Sector Demand
Worthington Steel Achieves Top Supplier Rating from John Deere for 14th Year
Gogo Faces Diverging Analyst Opinions Amid Guidance Changes
Regeneron Receives FDA Approval for Extended EYLEA HD Dosing
Regeneron Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration for extended dosing intervals of its EYLEA HD treatment. This approval applies to patients suffering from wet age-related macular degeneration and diabetic macular edema, allowing eligible individuals to receive injections as infrequently as every 20 weeks after a year of successful treatment.
The updated label for EYLEA HD is based on 96 weeks of efficacy and safety data, which supports the new dosing flexibility. This change positions EYLEA HD as a competitive option among other anti-VEGF treatments available in the market, potentially enhancing patient convenience and adherence to treatment regimens.
Investors are closely monitoring Regeneron as the company continues to navigate its valuation in the market, particularly in light of this new approval and the implications it may have for EYLEA HD's market performance.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News